The Lancet· @TheLancet · X·· 16 小时前精选AI 评分62
AI 导读
The Lancet 在 X 上发布，EASD2026 上公布的 petrelintide 数据达到具临床意义的体重下降，胃肠道耐受性与安慰剂总体相近，支持其作为长期肥胖疗法继续评估。相关结果发表于 The Lancet Diabetes & Endocrinology，链接为 http://spkl.io/60197pVbF。
推荐理由
EASD2026 上公布的 petrelintide 减重数据，为评估其作为长期肥胖疗法的可行性提供了早期临床依据。
正文
Presented at #EASD2026— Petrelintide achieved clinically meaningful weight reduction and had generally similar gastrointestinal tolerability to placebo, supporting further evaluation as a long-term obesity therapy. Read in The Lancet Diabetes & Endocrinology: http://spkl.io/60197pVbF
来源：The Lancet · x.com